WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Stock Ownership - Who owns Alnylam Pharmaceuticals?

Insider buying vs selling

Have Alnylam Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Phillip A. SharpDirector2024-02-29101$154.07
$15.56kSell
Phillip A. SharpDirector2024-02-29516$156.54
$80.77kSell
Phillip A. SharpDirector2024-02-2930,000$59.25
$1.78MBuy
Phillip A. SharpDirector2024-02-2913,005$150.60
$1.96MSell
Phillip A. SharpDirector2024-02-2913,557$151.43
$2.05MSell
Phillip A. SharpDirector2024-02-29915$152.40
$139.45kSell
Phillip A. SharpDirector2024-02-291,906$153.62
$292.80kSell
Indrani Lall FranchiniEVP CLO Secretary2024-02-289$157.30
$1.42kSell
Indrani Lall FranchiniEVP CLO Secretary2024-02-2866$156.38
$10.32kSell
Indrani Lall FranchiniEVP CLO Secretary2024-02-28111$155.45
$17.25kSell

1 of 12

ALNY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALNY insiders and whales buy or sell their stock.

ALNY Shareholders

What type of owners hold Alnylam Pharmaceuticals Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Capital World Investors12.84%16,174,563$2.46BInstitution
Ag Novartis11.75%14,800,620$2.25BInsider
Vanguard Group Inc9.48%11,943,895$1.82BInstitution
Sanofi8.38%10,554,134$1.60BInsider
Fmr LLC8.19%10,312,356$1.57BInstitution
Blackrock Inc6.77%8,521,115$1.29BInstitution
Wellington Management Group LLP5.73%7,214,198$1.10BInstitution
Baillie Gifford Co5.53%6,967,097$1.06BInstitution
Dodge Cox2.92%3,674,310$558.38MInstitution
Capital International Investors2.85%3,586,657$545.06MInstitution

1 of 3

ALNY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALNY80.88%19.12%Net SellingNet Selling
GMAB70.53%0.00%
RPRX51.02%16.51%Net SellingNet Selling
BNTX17.05%0.00%
BMRN98.08%1.64%Net SellingNet Selling

Alnylam Pharmaceuticals Stock Ownership FAQ

Who owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ: ALNY) is owned by 92.85% institutional shareholders, 21.94% Alnylam Pharmaceuticals insiders, and 0.00% retail investors. Ag Novartis is the largest individual Alnylam Pharmaceuticals shareholder, owning 14.80M shares representing 11.75% of the company. Ag Novartis's Alnylam Pharmaceuticals shares are currently valued at $2.29B.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.